Market Place
Sourcing Support
Coave Therapeutics Expands into US with Romain Pettenaro as VP of BD
23 Apr 2025 //
GLOBENEWSWIRE
Coave Therapeutics to Attend Upcoming Conferences
09 Apr 2025 //
GLOBENEWSWIRE
Coave Secures €32M Series A For Next-Gen Genetic Medicines
09 Jan 2025 //
GLOBENEWSWIRE
EyeDNA Receives FDA Rare Pediatric Disease Designation for Therapy
17 Dec 2024 //
GLOBENEWSWIRE
Coave Showcases Breakthrough In AAV Vectors At ESGCT 2024
22 Oct 2024 //
GLOBENEWSWIRE
Coave Therapeutics to Present ALIGATER™ Platform Data at Conferences
24 Sep 2024 //
GLOBENEWSWIRE
EyeDNA 24-Month Gene Therapy Data In Retinitis Pigmentosa At ARVO
07 May 2024 //
GLOBENEWSWIRE
Coave`s ALIGATER™ Platform for Suprachoroidal Ocular Gene Delivery
29 Apr 2024 //
GLOBENEWSWIRE
eyeDNA To Present HORA-PDE6b Data at ARVO 2024
25 Apr 2024 //
GLOBENEWSWIRE
Coave Therapeutics to Present at Upcoming Conferences
27 Mar 2024 //
GLOBENEWSWIRE
Coave Receives Grant from the ALS Association to Advance its CTx-TFEB Program
29 Feb 2024 //
GLOBENEWSWIRE
Coave appoints Leading World Experts to newly formed Scientific Advisory Board
12 Oct 2023 //
GLOBENEWSWIRE
Coave Therapeutics to Present at Upcoming Conferences
28 Sep 2023 //
GLOBENEWSWIRE
Coave Appoints Genetic Medicine Expert Lolita Petit, PhD as CSO
21 Sep 2023 //
GLOBENEWSWIRE
Coave announces Positive 12-months Data from Phase I/II Trial of CTx-PDE6b
31 May 2023 //
GLOBENEWSWIRE
Coave Therapeutics to Participate in Upcoming Conferences
17 May 2023 //
GLOBENEWSWIRE
Coave Therapeutics Demonstrates its Modified coAAV Vectors Outperform AAV9
04 May 2023 //
GLOBENEWSWIRE
Coave Therapeutics to Present at Upcoming Conferences
16 Mar 2023 //
GLOBENEWSWIRE
Coave Therapeutics Strengthens Board of Directors
20 Oct 2022 //
PRNEWSWIRE
Coave Therapeutics to Present at Cell and Gene Meeting on the Mesa
26 Sep 2022 //
PRNEWSWIRE
Coave Therapeutics to Present at Chardan`s 6th Annual Genetic Medicines
20 Sep 2022 //
PRNEWSWIRE
Coave to Collaborate with Institute of Neurodegenerative Diseases of Bordeaux
14 Sep 2022 //
PRNEWSWIRE
Coave Appoints Catherine Mathis & Julien Berger in Leadership Team
06 Sep 2022 //
PRNEWSWIRE
Coave Announces Formation of Scientific Advisory Board for Pipeline Strategy
30 Jun 2022 //
PRNEWSWIRE
Coave Therapeutics and ABL Enter Gene Therapy Collaboration
13 Jun 2022 //
CONTRACTPHARMA
Coave Therapeutics and ABL enter into strategic collaboration
07 Jun 2022 //
PRNEWSWIRE
Coave Therapeutics to Present at Cell & Gene Meeting on the Mediterranean
12 Apr 2022 //
PRNEWSWIRE
Coave Therapeutics Appoints Thomas Blaettler as CMO and Patricia Françon as COO
15 Nov 2021 //
PRNEWSWIRE
Théa pays for rights to Coave gene therapy in retinitis pigmentosa
17 Sep 2021 //
PRNEWSWIRE
Coave and Théa sign agreement for Europe for CTx-PDE6b, in retinitis pigmentosa
16 Sep 2021 //
PRNEWSWIRE
